Journal of Clinical Endocrinology & Metabolism, Vol 51, 915-920, Copyright © 1980 by Endocrine Society

ARTICLES

Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity

P Carayon, C Thomas-Morvan, E Castanas and M Tubiana

To characterize the relationship of the TSH receptor-adenylate cyclase system to differentiation in human thyroid cancers, adenylate cyclase and TSH binding were studied in membranes from primary and metastatis thyroid carcinomas of varying histological types (n = 33) and normal thyroids (n = 12). Membranes from differentiated carcinomas (n = 23) exhibit wide patient to patient variability; some membranes show entirely normal adenylate cyclase and TSH-binding characteristics, and other membranes exhibit decreased TSH stimulation of adenylate cyclase which is accompanied by either a normal or decrease TSH-binding site concentration. With respect to the TSH-binding site concentration and TSH stimulation of the adenylat cyclase, the well differentiated carcinomas are not significantly different from normal thyroids, whereas the moderately differentiated and the papillary carcinomas are significantly different (P < 0.001 and P < 0.001, respectively). Membranes from undifferentiated carcinomas (n = 5) and those from medullary carcinomas (n = 5) are characterized by an absence of both TSH binding and TSH stimulation of the adenylate cyclase. In conclusion, while a general relationship exists between the impairment of TSH responsiveness and the dedifferentiation process, no pattern of membrane alteration is specific for any histological type.

This article has been cited by other articles:

				G. C. Hovens, M. P. Stokkel, J. Kievit, E. P. Corssmit, A. M. Pereira, J. A. Romijn, and J. W. A. Smit Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2610 - 2615. [Abstract] [Full Text] [PDF]

				K. Boelaert, J. Horacek, R. L. Holder, J. C. Watkinson, M. C. Sheppard, and J. A. Franklyn Serum Thyrotropin Concentration as a Novel Predictor of Malignancy in Thyroid Nodules Investigated by Fine-Needle Aspiration J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4295 - 4301. [Abstract] [Full Text] [PDF]

				F. Santini, V. Bottici, R. Elisei, L. Montanelli, S. Mazzeo, F. Basolo, A. Pinchera, and F. Pacini Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4160 - 4165. [Abstract] [Full Text] [PDF]

				T. Metaye, E. Menet, J. Guilhot, and J.-L. Kraimps Expression and Activity of G Protein-Coupled Receptor Kinases in Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3279 - 3286. [Abstract] [Full Text] [PDF]

				T. Shiga, E. Tsukamoto, K. Nakada, K. Morita, T. Kato, M. Mabuchi, K. Yoshinaga, C. Katoh, Y. Kuge, and N. Tamaki Comparison of 18F-FDG, 131I-Na, and 201Tl in Diagnosis of Recurrent or Metastatic Thyroid Carcinoma J. Nucl. Med., March 1, 2001; 42(3): 414 - 419. [Abstract] [Full Text]